Kaposi sarcoma - null regimens

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 17:29, 15 March 2020 by Jwarner (talk | contribs) (Created page with "The purpose of this page is to provide references to "null therapy" such as placebo and observation. While not clinically relevant, these references provide further insight in...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

The purpose of this page is to provide references to "null therapy" such as placebo and observation. While not clinically relevant, these references provide further insight into the historical development of the treatment landscape. See the main KS page for current regimens.


All lines of therapy

Placebo

back to top

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Noy et al. 2005 (AMC 013) 1998-2001 Phase III (C) IM862 Seems to have superior TTP

No active antineoplastic treatment.

References

  1. AMC 013: Noy A, Scadden DT, Lee J, Dezube BJ, Aboulafia D, Tulpule A, Walmsley S, Gill P; AIDS Malignancy Consortium. Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team. J Clin Oncol. 2005 Feb 10;23(5):990-8. Epub 2004 Dec 14. link to original article PubMed
Retrieved from "https://hemonc.org/w/index.php?title=Kaposi_sarcoma_-_null_regimens&oldid=44713"